Principia Biopharma’s (Nasdaq: PRNB) stock gained more than 50% from our previous assessment. It was mostly driven by rumors about possible buyout from big pharma and hype among BTK inhibitors after Merck’s (Nasdaq: MRK) $2.7 billion bid for AqQule for their lead cancer drug candidate ARQ531 (BTKi).
Are these assumptions justified?
In the previous article I shared my thoughts in detail about the PRN1008 and its vague prospects in pemphigus treatment. Additional data recently shared by the company confirms our previous assessment.
Moreover, expected Phase 2 results of PRN2246/SAR442168 which is planned